Literature DB >> 29682729

Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats.

Ashish Dhir1, Michael A Rogawski1,2.   

Abstract

OBJECTIVE: Diazepam, administered by the intravenous, oral, or rectal routes, is widely used for the management of acute seizures. Dosage forms for delivery of diazepam by other routes of administration, including intranasal, intramuscular, and transbuccal, are under investigation. In predicting what dosages are necessary to terminate seizures, the minimal exposure required to confer seizure protection must be known. Here we administered diazepam by continuous intravenous infusion to obtain near-steady-state levels, which allowed an assessment of the minimal levels that elevate seizure threshold.
METHODS: The thresholds for various behavioral seizure signs (myoclonic jerk, clonus, and tonus) were determined with the timed intravenous pentylenetetrazol seizure threshold test in rats. Diazepam was administered to freely moving animals by continuous intravenous infusion via an indwelling jugular vein cannula. Blood samples for assay of plasma levels of diazepam and metabolites were recovered via an indwelling cannula in the contralateral jugular vein.
RESULTS: The pharmacokinetic parameters of diazepam following a single 80-μg/kg intravenous bolus injection were determined using a noncompartmental pharmacokinetic approach. The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively. Various doses of diazepam were continuously infused without or with an initial loading dose. At the end of the infusions, the thresholds for various behavioral seizure signs were determined. The minimal plasma diazepam concentration associated with threshold elevations was estimated at approximately 70 ng/mL. The active metabolites nordiazepam, oxazepam, and temazepam achieved levels that are expected to make only minor contributions to the threshold elevations. SIGNIFICANCE: Diazepam elevates seizure threshold at steady-state plasma concentrations lower than previously recognized. The minimally effective plasma concentration provides a reference that may be considered when estimating the diazepam exposure required for acute seizure treatment. Wiley Periodicals, Inc.
© 2018 International League Against Epilepsy.

Entities:  

Keywords:  continuous infusion; diazepam; pharmacokinetics; seizure threshold; time intravenous pentylenetetrazol seizure test

Mesh:

Substances:

Year:  2018        PMID: 29682729      PMCID: PMC5934328          DOI: 10.1111/epi.14069

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  33 in total

1.  Dosing feasibility and tolerability of intranasal diazepam in adults with epilepsy.

Authors:  Michael R Sperling; Kevin F Haas; Gregory Krauss; Hussam Seif Eddeine; Herbert R Henney; Adrian L Rabinowicz; Gary Bream; David Squillacote; Enrique J Carrazana
Journal:  Epilepsia       Date:  2014-08-25       Impact factor: 5.864

Review 2.  Is intravenous lorazepam really more effective and safe than intravenous diazepam as first-line treatment for convulsive status epilepticus? A systematic review with meta-analysis of randomized controlled trials.

Authors:  Francesco Brigo; Nicola Luigi Bragazzi; Susanna Bacigaluppi; Raffaele Nardone; Eugen Trinka
Journal:  Epilepsy Behav       Date:  2016-10-11       Impact factor: 2.937

Review 3.  Mechanisms of action of antiseizure drugs.

Authors:  Roger J Porter; Ashish Dhir; Robert L Macdonald; Michael A Rogawski
Journal:  Handb Clin Neurol       Date:  2012

4.  Species difference in diazepam metabolism and anticonvulsant effect.

Authors:  F Marcucci; A Guaitani; J Kvetina; E Mussini; S Garattini
Journal:  Eur J Pharmacol       Date:  1968-11       Impact factor: 4.432

5.  Acute seizure tests in epilepsy research: electroshock- and chemical-induced convulsions in the mouse.

Authors:  William J Giardina; Maciej Gasior
Journal:  Curr Protoc Pharmacol       Date:  2009-06

6.  Timed pentylenetetrazol infusion test: a comparative analysis with s.c.PTZ and MES models of anticonvulsant screening in mice.

Authors:  Sanjay N Mandhane; Keerthikumar Aavula; T Rajamannar
Journal:  Seizure       Date:  2007-06-13       Impact factor: 3.184

Review 7.  Classics in chemical neuroscience: diazepam (valium).

Authors:  Nicholas E Calcaterra; James C Barrow
Journal:  ACS Chem Neurosci       Date:  2014-02-27       Impact factor: 4.418

Review 8.  Clinical pharmacokinetics of diazepam.

Authors:  M Mandelli; G Tognoni; S Garattini
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

Review 9.  Benzodiazepine use in seizure emergencies: A systematic review.

Authors:  Sheryl R Haut; Syndi Seinfeld; John Pellock
Journal:  Epilepsy Behav       Date:  2016-09-06       Impact factor: 2.937

10.  Anticonvulsant potency of unmetabolized diazepam.

Authors:  H H Frey; W Löscher
Journal:  Pharmacology       Date:  1982       Impact factor: 2.547

View more
  4 in total

1.  Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats.

Authors:  Davin Rautiola; Patricia D Maglalang; Narsihmulu Cheryala; Kathryn M Nelson; Gunda I Georg; Jared M Fine; Aleta L Svitak; Katherine A Faltesek; Leah R Hanson; Usha Mishra; Lisa D Coles; James C Cloyd; Ronald A Siegel
Journal:  J Pharmacol Exp Ther       Date:  2019-03-05       Impact factor: 4.030

Review 2.  The unmet need for rapid epileptic seizure termination (REST).

Authors:  Aviva Asnis-Alibozek; Kamil Detyniecki
Journal:  Epilepsy Behav Rep       Date:  2020-11-25

Review 3.  Rescue therapies for seizure clusters: Pharmacology and target of treatments.

Authors:  Barry Gidal; Kamil Detyniecki
Journal:  Epilepsia       Date:  2022-09       Impact factor: 6.740

4.  Pharmacokinetics and safety of VALTOCO (NRL-1; diazepam nasal spray) in patients with epilepsy during seizure (ictal/peri-ictal) and nonseizure (interictal) conditions: A phase 1, open-label study.

Authors:  Robert Edward Hogan; Daniel Tarquinio; Michael R Sperling; Pavel Klein; Ian Miller; Eric B Segal; Adrian L Rabinowicz; Enrique Carrazana
Journal:  Epilepsia       Date:  2020-04-27       Impact factor: 5.864

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.